Supernus Q4 Revenue Rises 21.5% to $211.6M; EPS of $0.92 Beats Estimates
Supernus posted Q4 revenue of $211.57 million, up 21.5% year-over-year, beating consensus by 7.6%, and delivered EPS of $0.92 for a 228.6% surprise. Collaboration and royalty revenues climbed 166.6% to $20.7 million, while net product sales reached $158.1 million, down 5% from a year earlier.
1. Q4 Financial Performance
Supernus reported revenue of $211.57 million for the quarter ended December 2025, marking a 21.5% increase year-over-year, and achieved EPS of $0.92, far exceeding consensus estimates by 228.6%.
2. Product-Level Sales
Net product sales totaled $158.1 million, down 5% year-over-year, with Trokendi XR at $8.4 million (–43.2%), Oxtellar XR at $6.8 million (–48.5%) and APOKYN at $9.6 million (–52.2%), partially offset by Qelbree’s $81 million (up 8.9%).
3. Collaboration and Royalty Revenues
Collaboration revenue from ZURZUVAE reached $32.8 million versus estimates of $28.05 million, and royalty, licensing and other revenues surged 166.6% to $20.7 million, reflecting growing non-product streams.